GPCR Therapeutics Inc., founded in 2013, is a private biopharmaceutical company based in Seoul, South Korea. The company focuses on drug discovery, particularly in developing therapeutics that target G protein-coupled receptor (GPCR) heteromers for cancer treatment. Their leading compound, GPC-100/Burixafor, targets CXCR4, a GPCR often overexpressed in various cancers. GPCR Therapeutics has attracted significant investment, totaling $56.1 million, and collaborates with prominent venture capital firms such as LSK Investment and Medytox Venture Investment